Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas/Cardiome Anticipate Oct. 19 Vernakalant User Fee Date

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma and Cardiome Pharma anticipate an Oct. 19, 2007, user fee date for vernakalant (RSD1235), an intravenous formulation for acute conversion of atrial fibrillation, based upon a 10-month standard FDA review. Astellas resubmitted the NDA for vernakalant Dec 19

You may also be interested in...

Sanofi Dronedarone Re-Filing Anticipated In 2008 After FDA “Non Approvable” Letter

Sanofi-Aventis' resubmission of the atrial fibrillation medication Multaq is expected to include data from the ongoing ATHENA trial.

Astellas Will Give Cardiome Accelerated Milestone Payment For Atrial Fibrillation Drug

Revised agreement is a show of “confidence” following FDA’s refusal to file the original application for RSD1235.

FDA Refuses To File Cardiome/Astellas RSD1235 NDA

Cardiome says a third quarter resubmission of its anti-arrhythmic product will not require additional clinical data.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts